SnG Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SnG Biotech - overview
Established
2000
Location
Yongin, Gyeonggi, South Korea
Primary Industry
Medical Devices & Equipment
About
Founded in 2000 by Song Hoying, and based in South Korea, S&G Biotech Inc. , operates as a manufacturer of invasive medical devices such as seals, microcatheters, and gastrointestinal stents for surgical procedures. In December 2018, SnG Biotech raised KRW 2. 5 billion in venture funding from investor Hanwha Investment & Securities.
The firm’s product line includes bare stents, partial cover stents, full cover stents, colorectal stents, esophageal stents, graft extension stents, and other shapes of stents, radiomate access kits, guide wires, seals, etc.
Current Investors
Hanwha Investment & Securities, Cape Investment & Securities, Brick Investment
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices, Medical Supplies
Website
www.sngbio.co.kr
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
SnG Biotech - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 7,505,805,771 | 7,574,577,626 | 7,014,107,528 | 6,515,259,379 | 7,194,959,155 | 9,302,555,831 | - | - | - |
| % Revenue Growth (YoY) | - | 0.9% | (7.4%) | (7.1%) | 10.4% | 29.3% | - | - | - |
| EBITDA (USD) | 442,463,132 | (491,144,209) | (1,039,093,247) | 1,201,781,317 | 1,210,908,011 | 1,420,012,331 | - | - | - |
| Operating Income (USD) | 30,922,587 | (774,738,367) | (1,449,652,133) | 700,709,861 | 652,983,120 | 873,015,586 | - | - | - |
| Operating Margin | 0.4% | (10.2%) | (20.7%) | 10.8% | 9.1% | 9.4% | - | - | - |
| % EBITDA Margin | 5.9% | (6.5%) | (14.8%) | 18.4% | 16.8% | 15.3% | - | - | - |
| NET Income (USD) | (302,845,651) | (1,268,836,826) | (1,472,434,843) | 334,715,537 | 63,411,935 | 273,947,818 | - | - | - |
| % Net Margin | (4.0%) | (16.8%) | (21.0%) | 5.1% | 0.9% | 2.9% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.